CEBPA and acute myeloid leukemia: described a patient with isolated cauda equina relapse of FLT3-ITD and CEBPA-mutated AML who responded well to a multi-modality approach including IT chemotherapy, systemic methotrexate, sorafenib, and craniospinal irradiation, remaining in remission for over three years (2).